Cantor Fitzgerald Comments on Radius Health Inc’s FY2017 Earnings (RDUS)

Radius Health Inc (NASDAQ:RDUS) – Investment analysts at Cantor Fitzgerald decreased their FY2017 earnings per share (EPS) estimates for Radius Health in a report issued on Thursday. Cantor Fitzgerald analyst M. Goldstein now anticipates that the biopharmaceutical company will earn ($5.30) per share for the year, down from their prior forecast of ($5.05). Cantor Fitzgerald has a “Buy” rating and a $58.00 price target on the stock.

Several other analysts have also recently commented on the company. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. Citigroup assumed coverage on Radius Health in a research report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 target price for the company. ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Jefferies Group decreased their target price on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research report on Friday, November 3rd. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $48.00.

Shares of Radius Health (NASDAQ:RDUS) opened at $38.02 on Monday. The company has a market capitalization of $1,695.39, a price-to-earnings ratio of -7.00 and a beta of 1.10. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 12-month low of $24.66 and a 12-month high of $49.16.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same period in the previous year, the business posted ($1.07) earnings per share.

In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was acquired at an average cost of $29.15 per share, for a total transaction of $1,457,500.00. Following the completion of the acquisition, the insider now owns 5,648,799 shares in the company, valued at $164,662,490.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $28.09 per share, with a total value of $49,944.02. Following the completion of the acquisition, the vice president now owns 2,278 shares of the company’s stock, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 158,578 shares of company stock valued at $4,659,916. 15.00% of the stock is owned by corporate insiders.

Several large investors have recently made changes to their positions in RDUS. Legal & General Group Plc raised its holdings in shares of Radius Health by 14.5% during the second quarter. Legal & General Group Plc now owns 13,372 shares of the biopharmaceutical company’s stock worth $605,000 after acquiring an additional 1,697 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Radius Health by 14.1% during the second quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter. Swiss National Bank raised its holdings in shares of Radius Health by 8.7% during the second quarter. Swiss National Bank now owns 54,000 shares of the biopharmaceutical company’s stock worth $2,442,000 after acquiring an additional 4,300 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Radius Health by 24.2% during the second quarter. Teachers Advisors LLC now owns 67,101 shares of the biopharmaceutical company’s stock worth $3,035,000 after acquiring an additional 13,077 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its holdings in shares of Radius Health by 17.3% during the second quarter. TIAA CREF Investment Management LLC now owns 100,526 shares of the biopharmaceutical company’s stock worth $4,547,000 after acquiring an additional 14,796 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/01/22/cantor-fitzgerald-comments-on-radius-health-incs-fy2017-earnings-rdus.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply